Lepzacitinib
Alternative Names: ATI-1777Latest Information Update: 18 Jan 2024
At a glance
- Originator Confluence Life Sciences
- Developer Aclaris Therapeutics
- Class Anti-inflammatories; Skin disorder therapies; Small molecules
- Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Atopic dermatitis
- No development reported Alopecia areata; Vitiligo
Most Recent Events
- 18 Jan 2024 ATI 1777 is available for licensing as of 17 Jan 2024. https://www.aclaristx.com/pipeline/
- 10 Jan 2024 Efficacy, adverse events and pharmacokinetics data from a phase II trial in Atopic dermatitis released by Aclaris Therapeutics
- 14 Nov 2023 Aclaris Therapeutics completes a phase II trial in Atopic Dermatitis (In adolescents, In adults, In the elderly) in USA (Topical) (NCT05432596)